North Asia

A core product for Type 2 diabetes is expected to commercially launch in mainland China by the end of this year, subject to regulatory approval; CICC led the transaction.

The bill for fiat-referenced stablecoins is expected to come into effect later this year.

The US giant will pay the money upfront for distribution rights for SSGJ-707 outside of China; the deal could be worth up to $4.8bn and Pfizer will also invest $100m into the HKEX listed firm.

The dual listing will help keep momentum in Hong Kong's equity markets, with the majority of the $4.5bn proceeds raised by the Shenzhen based global EV player set to help build a factory in Hungary; a greenshoe option takes the raising to $5.2bn.

The issuance from the Hong Kong conglomerate, formerly known as NWS Holdings, was to finance the redemption of its outstanding offshore capital securities by its subsidiary.

The Hong Kong-headquartered Asian life insurer, backed by billionaire Richard Li, has made several similar filings in recent years without triggering an IPO.

Minority owner Partners Group said the IPO proceeds will be used to further grow the Hangzhou-headquartered restaurant's 493 outlets and establish a centralised food processing facility; Clifford Chance, Citi and CMB International Capital were involved in the deal.

The Japanese giant will make cost savings of ¥500bn and reduce its workforce by 20,000, and its number of plants from 17 to 10 by FY 2027, after a net loss of ¥670.9bn in FY 2024.

$400m has been allocated to support Digital Halo, which has assets in the Philippines and Malaysia; the Swiss PE firm is also expanding its data centre footprint in Australia.